drugset / Trial / NCT02536417

Efficacy of Melatonin in Decreasing the Incidence of Delirium in End of Life Patients

NCT02536417

Phase 3 Completed 19 enrolled Fraser Health
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine if melatonin administration to end-of-life patients is effective in preventing the development of delirium compared with those who do not receive this treatment. Delirium is a difficult to control symptom commonly seen in patients at the end-of-life. A person who is delirious is unable to think clearly and cannot make sense of what is going on around him/her.

Timeline

Start
2016-06-29
Primary completion
2020-09
Completion
2020-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Melatonin Small molecule 0.5 mg

Indications